文献速递神经MR

AI工具提升标准剂量脑MRI对比剂增强病灶可视化的多中心回顾研究

Evaluation of an AI-powered tool in improving lesion visualization on standard-dose contrast-enhanced brain MRI: a retrospective, multicenter study.
PubMed 文献 · AJNR Am J Neuroradiol · 2026-08-13

本研究为回顾性多中心多阅片者研究,纳入86例接受标准剂量对比增强脑MRI的成人患者,使用深度学习后处理工具AiMIFY生成对比增强图像。结果显示AiMIFY图像在CNR、LBR和CEP上均显著高于标准剂量增强后图像(均P<0.001),主观评估边界勾画、内部形态和对比增强均显著改善(均P<0.05),尤其对小于10mm的小病灶主观评分更高。

要点

  • AiMIFY可提升标准剂量增强脑MRI的病灶对比度,利于小病灶显示。
  • 主观评估边界、内部形态和增强程度均改善,诊断信心可能提高。
  • 多数病例偏好AiMIFY图像,但读者间偏好率差异较大。

关键影像表现/征象

  • AiMIFY处理图像在所有阅片者中均显示更高的对比噪声比(CNR)、病灶-脑比值(LBR)和对比增强百分比(CEP)。
  • 主观评估显示边界勾画、内部形态和对比增强均显著改善(均P<0.05)。
  • 亚组分析显示小于10mm的小病灶在AiMIFY图像上主观评分 consistently 更高(均P<0.05)。

诊断标准与关键数值

  • 定量指标包括CNR、LBR和CEP,AiMIFY图像较标准增强后图像平均分别增加495.16%、58.94%和160.55%。
  • 主观图像质量采用Likert量表评估边界勾画、内部形态和对比增强。
  • 总体诊断偏好记录为多数病例偏好AiMIFY图像(各阅片者分别为84.9%、29.1%和68.6%;均P<0.001)。

临床应用与阅片要点

  • 可考虑将AI后处理作为标准剂量增强MRI的辅助手段,提升病灶对比度。
  • 对小病灶(<10mm)的检出和评估可能获益更多。
  • 需注意不同阅片者对AI图像的偏好存在差异,应结合常规图像综合判断。

局限性

  • 回顾性研究设计。
  • 样本量有限(86例)。
  • 仅评估了单一AI工具(AiMIFY)的性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Artificial intelligence (AI) algorithms have been used to synthesize standard-dose images from low-dose images in brain MRI, but have less been evaluated to boost standard-dose contrast to approximate higher-dose effect. This study aims to evaluate the performance of a deep learning-based post-processing tool (AiMIFY) in enhancing contrast and improving lesion visualization on standard-dose contrast-enhanced brain MRI.

MATERIALS AND METHODS: In this retrospective, multicenter, multireader study, 86 adult patients who underwent standard-dose contrast-enhanced brain MRI were included. Pre-contrast and post-contrast three-dimensional T1-weighted images were processed using AiMIFY to generate contrast-boosting images. Three independent neuroradiologists performed blinded assessments. Quantitative metrics, including contrast-to-noise ratio (CNR), lesion-to-brain ratio (LBR), and contrast enhancement percentage (CEP), were measured. Subjective image quality (border delineation, internal morphology, and contrast enhancement) were evaluated using a Likert scale. The overall diagnostic preference was recorded. Comparisons between standard post-contrast and AiMIFY-processed images were performed using the Wilcoxon signed-rank test.

RESULTS: AiMIFY-processed images demonstrated significantly higher CNR, LBR, and CEP compared with standard-dose post-contrast images across all readers (all P < 0.001), with mean increases of 495.16%, 58.94%, and 160.55%, respectively. Subjective assessments showed significant improvements in border delineation, internal morphology, and contrast enhancement (all P < 0.05). Subgroup analysis of small lesions (< 10 mm) revealed consistently higher subjective scores for AiMIFY-processed images (all P < 0.05). AiMIFY-processed images were preferred in the majority of cases (84.9%, 29.1%, and 68.6% across readers; all P < 0.001).

CONCLUSION: Deep learning-based enhancement using AiMIFY significantly improves lesion conspicuity on standard-dose contrast-enhanced brain MRI, with notable benefits for small lesions. This approach may represent an adjuvant to standard-dose MRI to enhance diagnostic confidence while avoiding increased contrast agent exposure.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Gao Y, Chen B, Wen C, et al. Evaluation of an AI-powered tool in improving lesion visualization on standard-dose contrast-enhanced brain MRI: a retrospective, multicenter study. AJNR Am J Neuroradiol. 2026. PMID: 42595464. doi:10.3174/ajnr.A9591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。